Antineoplastic Combined Chemotherapy Protocols/pharmacology; Boronic Acids/pharmacology; Carcinoma, Non-Small-Cell Lung/drug therapy; Down-Regulation/drug effects; Lung Neoplasms/drug therapy; Proteasome Inhibitors; Pyrazines/pharmacology; Topoisomerase I Inhibitors; Apoptosis/drug effects; Apoptosis/genetics; Boronic Acids/administration & dosage; Bortezomib; Camptothecin/administration & dosage; Camptothecin/analogs & derivatives; Camptothecin/pharmacology; Carcinoma, Non-Small-Cell Lung/enzymology; Carcinoma, Non-Small-Cell Lung/genetics; Cell Line, Tumor; DNA Damage; Drug Synergism; Humans; I-kappa B Proteins/genetics; Inhibitor of Apoptosis Proteins; Irinotecan; Lung Neoplasms/enzymology; Lung Neoplasms/genetics; Microtubule-Associated Proteins/metabolism; Mutation; NF-KappaB Inhibitor alpha; NF-kappa B/genetics; NF-kappa B/metabolism; Neoplasm Proteins/metabolism; Protease Inhibitors/pharmacology; Pyrazines/administration & dosage; Survivin; Transfection